TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12133539
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CYC) pulse therapy
Study: 30623248
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation with amorphous form of BCS 2 class drug
Study: 30623248
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug product with crystalline form
Study: 17547760
Drug: Active strategy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active strategy (training module with administration of the guideline)
Study: 17547760
Drug: Passive dissemination
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive dissemination (administration of the guideline only)
Study: 9861607
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate supplementation (200 micrograms daily)
Study: 2192073
Drug: Pulse-dosed antibiotics
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-dosed antibiotics administered in a single daily dose
Study: 31335979
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus liraglutide 0.6 mg/day
Study: 28884856
Drug: Adalimumab trough
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab trough level of 5.0 μg/mL
Study: 21641354
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ABMMNC treatment)
Study: 19254211
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy of IHD
Study: 16442924
Drug: Clopidogrel (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (loading dose 300 mg followed by 75 mg/d for 8 weeks)
Study: 15630287
Drug: Isoflavone supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplements (40mg/d)
Study: 11332874
Drug: 1.12 mg
Normalized name: Kytril 1 MG (granisetron hydrochloride 1.12 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.12 mg chlorphenamine maleate (0.4% nasal spray)
Study: 11332874
Drug: 2.24 mg
Normalized name: Kytril 2 MG (granisetron hydrochloride 2.24 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.24 mg chlorphenamine maleate (0.4% nasal spray)
Study: 11332874
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg chlorphenamine maleate (tablets)
Study: 9444443
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) at 50, 100, or 200 micrograms once daily for 7 days
Study: 9444443
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) at 50, 100, or 200 micrograms once daily for 14 days
Study: 10654982
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFNS)
Study: 9037289
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of vasodilators
Study: 9037289
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection of vasodilators
Study: 9181442
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection
Study: 9037289
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection of low volume drug
Study: 2667859
Drug: Oral xylose
Normalized name: Xylose
DrugBank: Xylose (DB09419)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral xylose
Study: 2667859
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose and xylose
Study: 822547
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampicin daily for 12 weeks followed by once-weekly for 12 months
Study: 822547
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg rifampicin once-weekly for 12, 18 or 24 months
Study: 822547
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg rifampicin for longer than 1 year
Study: 9578186
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampicin
Study: 822547
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg rifampicin
Study: 822547
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg rifampicin for 24 months
Study: 16683672
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel with Ca(OH)2
Study: 15459587
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine 140 microg/kg/min
Study: 12959311
Drug: ACE inhibition
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibition with fosinopril, 20 mg day(‐1)
Study: 2841818
Drug: estrogen-gestagen sequential
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: estrogen-gestagen sequential therapy
Study: 2841818
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (all therapies)
Study: 26108222
Drug: Oral lysergic
Normalized name: D-lysergic acid 1-butanolamide
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lysergic acid diethylamide (200 μg)
Study: 24074332
Drug: Combination budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination budesonide/formoterol inhaler according to a single inhaler regimen (SMART)
Study: 20461422
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 μg/day) + Alendronate (5 mg/day)
Study: 16538542
Drug: Dose-dense sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense sequential chemotherapy (3 cycles of epirubicin 110 mg/m2 followed by 3 cycles of paclitaxel 250 mg/m2 followed by 3 cycles of intensified CMF)
Study: 16538542
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (4 cycles of epirubicin followed by 4 cycles of CMF)
Study: 14499022
Drug: Spiritual healing
Normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spiritual healing treatment (3 weekly sessions lasting approximately 30 minutes each)
Study: 10920469
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean daily dose, 2.2 +/- 0.7 mg/d)
Study: 8612028
Drug: SSZ (2g/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSZ (2g/day) and pulses of MP (5 mg/kg)
Study: 6692287
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tamoxifen daily
Study: 29943719
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (5 doses of 2.7 × 10^5 PfSPZ at 0, 4, 8, 12, and 20 weeks)
Study: 27338955
Drug: TRABC in
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Trac Tabs 2x]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRABC in addition to conventional Western treatment
Study: 20353028
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western treatment
Study: 20191783
Drug: Interval between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval between last dose of relaxant and arrival in PACU
Study: 12025888
Drug: 10-min infusion
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-min infusion of topotecan (1.5 mg/m2/d for 5 days of a 21-day course)
Study: 12025888
Drug: 10-min infusion
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-min infusion of topotecan
Study: 2177970
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMH)
Study: 28284221
Drug: Hormonal contraceptive
Normalized name: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal contraceptive method (DMPA, oral pills, norplant)
Study: 23585423
Drug: Enalapril at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril at 0.4 mg/kg/day for 1 year
Study: 17694046
Drug: Intraligamental injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamental injection (ITR)
Study: 17694046
Drug: Infiltration injection
Normalized name: LIDOCAINE HYDROCHLORIDE 0.02 g in 1 mL INFILTRATION INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration injection (IFL)
Study: 15037668
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous apomorphine therapy at a rate of 4 mg/h
Study: 15037668
Drug: Intranasal apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal apomorphine (2 to 5 mg per inhalation)
Study: 15037668
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg subcutaneous apomorphine
Study: 15037668
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg sublingual apomorphine
Study: 15037668
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg rectal apomorphine suppository
Study: 11232013
Drug: Rosiglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 2 mg bd
Study: 11232013
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg bd
Study: 3165190
Drug: Chemomechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemomechanical preparation (3% H2O2 and 5.25% NaOCl as irrigants, no intracanal medication)
Study: 27842579
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT) before surgical consultation
Study: 21358087
Drug: RT-HT (Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT-HT (Radiation Therapy with Hyperthermia)
Study: 21358087
Drug: RT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT alone (Radiation Therapy)
Study: 17596638
Drug: Morning or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning or afternoon bright light exposure for 1 hr daily (Monday‐Friday) for 10 weeks
Study: 10687880
Drug: HRT group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT group: Sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU/day) + calcium lactate (500 mg/day) (n = 232)
Study: 10687880
Drug: Non-HRT group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HRT group: Calcium lactate (500 mg/day) alone or in combination with vitamin D3 (100-300 IU/day) (n = 232)
Study: 9210905
Drug: BLP (lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLP (lactobacillus casei preparation)
Study: 8398322
Drug: Ondansetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (3 doses of 8 mg IV at 0, 4, and 8 hours)
Study: 8398322
Drug: Metoclopramide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (3 mg/kg IV loading dose followed by 0.5 mg/kg/h for 8 hours)
Study: 3081361
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 80 mg aerosolized
Study: 30257802
Drug: Vorapaxar (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar (2.5 mg orally daily for 12 weeks)
Study: 27282594
Drug: Local methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local methylprednisolone injections (n=20)
Study: 22295869
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 20 mg/kg PO q8h for 16 weeks
Study: 20738476
Drug: Commercially funded
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially funded trials (pharmaceutical companies)
Study: 19255990
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen suspension (10, 5, 5 mg/kg every 24 hours)
Study: 9014674
Drug: Sequential avulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential avulsion of the long saphenous vein
Study: 6435067
Drug: tinnitus instrument
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tinnitus instrument (a combination device consisting of a tinnitus masker and a hearing aid)
Study: 30001740
Drug: DMARD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD treatment (starting with methotrexate monotherapy with prednisolone bridging)
Study: 24812043
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg or 1.25 mg
Study: 24812043
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon β‐1a (IFNβ‐1a)
Study: 17289895
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cisplatin and vinorelbine
Study: 9485087
Drug: 20 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg/day oral type II collagen (CII)
Study: 9485087
Drug: 100 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg/day oral type II collagen (CII)
Study: 9485087
Drug: 500 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg/day oral type II collagen (CII)
Study: 9485087
Drug: 2,500 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,500 microg/day oral type II collagen (CII)
Study: 2548552
Drug: Cilazapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (5 mg oral)
Study: 28086917
Drug: Resveratrol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (up to 1 g by mouth twice daily)
Study: 26338810
Drug: Fingolimod 1.25/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25/5 mg
Study: 19958431
Drug: Jessner's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jessner's solution peel
Study: 19958431
Drug: Topical hydroquinone
Normalized name: hydroquinone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydroquinone 2% and kojic acid
Study: 1715809
Drug: 1% gamma‐BHC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% gamma‐BHC emulsion at 10.0 ml
Study: 1715809
Drug: 1% gamma‐BHC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% gamma‐BHC emulsion at 5.0 ml
Study: 1715809
Drug: 1% gamma‐BHC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% gamma‐BHC emulsion at 2.5 ml
Study: 1715809
Drug: Overall infestation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall infestation rate 5 months after treatment
Study: 30776996
Drug: Ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor and Aspirin
Study: 22826530
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (10 mL)
Study: 22826530
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% with dexmedetomidine 1 μg/kg (10 mL)
Study: 20088935
Drug: YM150 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM150 5 mg
Study: 17663737
Drug: YM150 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM150 10 mg
Study: 17663737
Drug: YM150 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM150 30 mg
Study: 17663737
Drug: YM150 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM150 60 mg
Study: 20088935
Drug: YM150 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM150 120 mg
Study: 10463404
Drug: Drop test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drop test with varying test solutions
Study: 10463404
Drug: Drop test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drop test with increased viscosity of test solution
Study: 8531592
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bolus (250 micrograms) and infusion (250 micrograms/h for 65 min) of somatostatin
Study: 26814251
Drug: Alternative method
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative method of local anesthesia injection
Study: 26814251
Drug: Traditional method
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional method of local anesthesia injection
Study: 26814251
Drug: Treatment needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment needle size
Study: 26814251
Drug: Pain at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain at one inch of treatment needle insertion
Study: 12394202
Drug: Intranasal budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal budesonide, applied to each nostril, once daily for eight weeks
Study: 8610775
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of intravaginal prostaglandin E2 gel for 5 consecutive days
Study: 2191763
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (2500 cGy over 5 to 7 days)
Study: 28836895
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release
Study: 27409603
Drug: Sarcosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (2 grams daily)
Study: 9693934
Drug: Metformin (M;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (M; n = 15)
Study: 1961959
Drug: Propofol, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol, 2.5 mg/kg
Study: 17171863
Drug: Thiamylal, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal, 4 mg/kg
Study: 22027664
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) administered in doses from 2250 to 3000 mg per day
Study: 16532095
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg of elemental zinc/cap/day) for 3 months
Study: 11361230
Drug: Absorbitol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbitol (250 mg) 3 times a day before meals
Study: 27367436
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine cigarettes (VLNCs; 0.4 mg nicotine/g tobacco) for 6 weeks
Study: 18628485
Drug: CC (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (conventional cigarette)
Study: 16816829
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (1 Hz at 110% of motor threshold) administered over the left dorso-lateral prefrontal cortex for 10 sessions.
Study: 16816829
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS administered over the left dorso-lateral prefrontal cortex for 10 sessions.
Study: 12932382
Drug: Immediate systemic
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate systemic therapy with oral chlorambucil 10 mg per day continuously
Study: 12932382
Drug: Observation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation with systemic therapy delayed until disease progression
Study: 10190655
Drug: Vapreotide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapreotide (1.5 mg day(-1) s.c.) for 7 days
Study: 2502385
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (20 mg/day for adult)
Study: 2502385
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (80 mg/day for adult)
Study: 2502385
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (20 mg/day for adult) in patients with Lennox-Gastaut syndrome
Study: 2502385
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (80 mg/day for adult) in patients with Lennox-Gastaut syndrome
Study: 8984133
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once a day
Study: 14739127
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid (2 g, n=8)
Study: 11434163
Drug: Platelet activation
Normalized name: Platelet activation dependent granule external membrane protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet activation assessment at the onset of INS and after 2 weeks of therapy
Study: 8042724
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg intramuscularly before surgery, repeated at 4 and 10 hours)
Study: 8042724
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg intravenously after assessing block height)
Study: 18443928
Drug: Control (penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (penicillin V, cefuroxime, or amoxicillin/clavulanate)
Study: 19060427
Drug: Allicor (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicor (600 mg daily)
Study: 11171786
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (ramipril 10 mg/d)